Table 2.

Antimicrobial susceptibility profile of Salmonella isolates (n = 82) in the present study.

Antimicrobial Agents	Susceptible (S)		Intermediate (I)		Resistance (R)		I + R
	Number of Isolates	%	Number of Isolates	%	Number of Isolates	%
Penicillins
Ampicillin (AMP, 10 μg)	70	85.37	4	4.88	8	9.76	14.63
Amoxycillin/clavulanate (AMC, 20/10 µg)	45	54.88	3	3.66	34	41.46	45.12
Piperacillin/tazobactam (PTZ, 100/10 μg)	69	84.15	6	7.32	8	8.54	15.85
Aminoglycosides
Amikacin (AMK, 30 μg)	53	64.63	7	8.54	22	26.83	35.37
Gentamicin (GEN, 10 μg)	47	57.32	8	9.76	27	32.93	42.68
Cephalosporins
Cefuroxime (CFX, 30 μg)	46	56.10	10	12.20	26	31.71	43.90
Cefuroxime axetil (CFA, 30 μg)	44	53.66	21	25.61	17	20.73	46.34
Ceftriaxone (CTR, 30 μg)	43	52.44	6	7.32	33	40.24	47.56
Cefoperazone/sulbactam (CFS, 75/30 μg)	42	51.22	33	40.24	7	8.54	48.78
Cefepime (CFP, 30 μg)	38	46.34	29	35.37	15	18.29	53.66
Carbapenems
Ertapenem (ETP, 10 μg)	45	54.88	32	39.02	5	6.10	45.12
Imipenem (IMP, 10 μg)	56	68.29	5	6.10	21	25.61	31.71
Meropenem (MPM, 10 μg)	48	58.54	6	7.32	28	34.15	41.46
Tetracyclines
Tigecycline (TIG, 15 μg)	23	28.05	8	9.76	51	62.20	71.95
Fluoroquinolones
Ciprofloxacin (CIP, 5 μg)	16	19.51	6	7.32	60	73.17	80.49
Nitrofurans
Nitrofurantoin (NIT, 300 µg)	60	73.17	8	9.76	14	17.07	26.83
Polymyxins
Colistin (COL, 10 μg)	0	0.00	6	7.32	76	92.68	100.00
Folate Pathway Inhibitors
Trimethoprim/Sulfamethoxazole (SXT, 1.25/23.75 µg)	23	28.05	9	10.98	50	60.98	71.95

% is the percentage (number of isolates/total number of isolates). CLSI zone diameter (in mm) interpretive criteria.